(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
12 January 2012 (12.01.2012)

PCT

(10) International Publication Number
WO 2012/004698 A1

(51) International Patent Classification:
C07D 401/04 (2006.01) *A61P 25/22* (2006.01)
A61K 31/506 (2006.01) *A61P 25/28* (2006.01)
A61P 25/08 (2006.01) *A61P 29/02* (2006.01)

(21) International Application Number:
PCT/IB2011/052686

(22) International Filing Date:
20 June 2011 (20.06.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/362,505 8 July 2010 (08.07.2010) US

(71) Applicant *(for all designated States except US)*: **PFIZER INC.** [US/US]; 235 East 42nd Street, New York, New York 10017 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **CLAFFEY, Michelle, Marie** [US/US]; Pfizer Global Research and Development, Eastern Point Road, Groton, Connecticut 06340 (US). **DAVOREN, Jennifer, Elizabeth** [US/US]; Pfizer Global Research and Development, Eastern Point Road, Groton, Connecticut 06340 (US). **LOWE, John, Adams III** [US/US]; 28 Coveside Lane, Stonington, Connecticut 06378 (US). **MATHER, Robert, Joseph** [US/US]; Pfizer Global Research and Development, Eastern Point Road, Groton, Connecticut 06340 (US).

(74) Agent: **KLEIMAN, Gabriel, L.**; Pfizer Inc. 235 East 42nd Street, New York, New York 10017 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to the identity of the inventor (Rule 4.17(i))*

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*


— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

(54) Title: PIPERIDINYL PYRIMIDINE AMIDES AS KV7 POTASSIUM CHANNEL OPENERS



(I)

(57) Abstract: The present invention relates to compounds of Formula (I) as described herein or a pharmaceutically acceptable salt thereof, pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof and methods of treating, or manufacture of a medicament to treat, a disease, disorder, or condition of the central nervous system, including bipolar disorder, depressive disorders, anxiety disorders, cognitive disorders, pain disorders, urogentital disorder, and epilepsy, among the other diseases, disorders or conditions discussed herein as mono-therapy or in combination with another active pharmaceutical ingredient.

WO 2012/004698 A1